In vivo two-photon imaging

KM Konnor P. McDowell
AB Andrée-Anne Berthiaume
TT Taryn Tieu
DH David A. Hartmann
AS Andy Y. Shih
ask Ask a question
Favorite

Imaging was performed with a Bruker Investigator and a Spectra-Physics Insight X3 laser source. For studies examining arteriolar vasodynamics, chlorprothixene sedation was used. We injected 30 µL of 1 mg/mL chlorprothixene solution intramuscularly (thigh muscle), immediately after cranial window surgery with isoflurane (Sigma C1671). We then injected 2 MDa FITC-dextran (FD2000S; Sigma-Aldrich) retro-orbitally under 2% isoflurane, turned off the isoflurane, and waited 15–30 minutes for chlorprothixene to take effect. FITC-dextran was prepared at a concentration of 5% (w/v) and 0.03 mL was injected. For studies examining capillary diameter, mice were imaged under isoflurane anesthesia (~1.25% MAC in medical air), which leaves the mouse anesthetized but reactive to light toe pinch during imaging. In isoflurane experiments, 2 MDa FITC-dextran was also used for vascular labeling. Body temperature was maintained at 37 °C with a feed-back regulated heat pad. In vivo imaging of FITC-dextran was performed at 800-nm excitation. High-resolution imaging of microvasculature was performed using a 20-X, 1.0 NA water-immersion objective lens (Olympus XLUMPLFLN 20XW). Lateral sampling (x, y) was ~1 µm/pixel (arterioles) or 0.5 µm/pixel (capillaries), and axial sampling (z) was 1 µm/pixel. All lumen diameter quantifications were made in the lateral plane. When imaging with the 20-X objective, laser power ranged between 20–100 mW at the sample, with higher powers required for greater cortical depth. To ablate a single capillary pericyte, a restricted line-scan was applied to only the soma of the target pericyte for ~60 seconds at a power of ~50 mW and excitation wavelength of 725-nm, as previously described (22).

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A